(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-[(tert-butyldimethylsilyl)oxy]-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2R)-2-methylbutanoate

• ChemBase编号: 163358
• 分子式: C30H50O5Si
• 平均质量: 518.8005
• 单一同位素质量: 518.34275123
• SMILES: [C@@H]1(C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]1C[C@H](CC(=O)O1)O[Si](C(C)(C)C)(C)C)C)OC(=O)[C@@H](CC)C
• Canonical SMILES: CC[C@H](C(=O)O[C@H]1C[C@@H](C)C=C2[C@H]1[C@@H](CC[C@@H]1C[C@H](CC(=O)O1)O[Si](C(C)(C)C)(C)C)[C@H](C=C2)C)C
• InChI: InChI=1S/C30H50O5Si/c1-10-20(3)29(32)34-26-16-19(2)15-22-12-11-21(4)25(28(22)26)14-13-23-17-24(18-27(31)33-23)35-36(8,9)30(5,6)7/h11-12,15,19-21,23-26,28H,10,13-14,16-18H2,1-9H3/t19-,20+,21-,23+,24+,25-,26-,28-/m0/s1
• InChIKey: YZUJIMXHROAZNZ-LLDGAUDVSA-N

名称和登记号

名称

• IUPAC标准名: (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-[(tert-butyldimethylsilyl)oxy]-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2R)-2-methylbutanoate
• IUPAC传统名: (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-[(tert-butyldimethylsilyl)oxy]-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2R)-2-methylbutanoate
• 别名: [1S-[1.alpha.(S*),3.alpha.,7.beta.,8.beta.(2S*,4S*),8a.beta.]]-2-Methyl-butanoic Acid 8-[2-[4-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]tetrahydro-6-oxo-2H-pyran-2-yl]ethyl]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-1-naphthalenyl Ester; 4-O-tert-Butyldimethylsilyl Epi Lovastatin

登记号

• CAS号: 82978-03-8
• PubChem SID: 162257493
• PubChem CID: 71314413

理论计算性质

• 质子受体: 3
• 质子供体: 0
• LogD (pH = 5.5): 6.331
• LogD (pH = 7.4): 6.331
• Log P: 6.331
• 摩尔折射率: 143.0305 cm^3
• 极化性: 58.466503 Å^3
• 极化表面积: 61.83 Å^2
• 可自由旋转的化学键: 10
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: Dichloromethane; Methanol

详细说明

Toronto Research Chemicals - B691355

Protected Lovastatin impurity; an antihypercholesterolemic compound.

参考文献

• Hoffman, W., et al.: J. Med. Chem., 29, 849 (1986)